# 1 M-DATA: A Statistical Approach to Jointly Analyzing De Novo

# 2 Mutations for Multiple Traits

3	Yuhan Xie <sup>1#</sup> , Mo Li <sup>1#</sup> , Weilai Dong <sup>2</sup> , Wei Jiang <sup>1</sup> , Hongyu Zhao <sup>1,3*</sup>
4	
5	Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA 06510
6	<sup>2</sup> Department of Genetics, Yale School of Medicine, New Haven, CT, USA 06510
7	<sup>3</sup> Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA
8	06511
9	
10	<sup>#</sup> These authors contributed to this work equally
11	* To whom correspondence should be addressed:
12	Prof Hongyu Zhao
13	Department of Biostatistics, Yale School of Public Health, 60 College Street, New Haven, CT,
14	06520, USA
15	Email: hongyu.zhao@yale.edu
16	
17	
10	
10	
19	
20	
21	
22	
22	
23	
24	
05	
25	

### 26 Abstract

27 Recent studies have demonstrated that multiple early-onset diseases have shared risk genes. 28 based on findings from *de novo* mutations (DNMs). Therefore, we may leverage information 29 from one trait to improve statistical power to identify genes for another trait. However, there are 30 few methods that can jointly analyze DNMs from multiple traits. In this study, we develop a 31 framework called M-DATA (Multi-trait framework for De novo mutation Association Test with 32 Annotations) to increase the statistical power of association analysis by integrating data from 33 multiple correlated traits and their functional annotations. Using the number of DNMs from 34 multiple diseases, we develop a method based on an Expectation-Maximization algorithm to 35 both infer the degree of association between two diseases as well as to estimate the gene 36 association probability for each disease. We apply our method to a case study of jointly 37 analyzing data from congenital heart disease (CHD) and autism. Our method was able to 38 identify 23 genes for CHD from joint analysis, including 12 novel genes, which is substantially 39 more than single-trait analysis, leading to novel insights into CHD disease etiology.

40

### 41 Author Summary

42 Congenital heart disease (CHD) is the most common birth defect. With the development of new 43 generation sequencing technology, germline mutations such as *de novo* mutations (DNMs) with 44 deleterious effects can be identified to aid in discovering the genetic causes for early on-set 45 diseases such as CHD. However, the statistical power is still limited by the small sample size of 46 DNM studies due to the high cost of recruiting and sequencing samples, and the low occurrence 47 of DNMs given its rarity. Compared to DNM analysis for other diseases, it is even more 48 challenging for CHD given its genetic heterogeneity. Recent research has suggested shared 49 disease mechanisms between early-onset neurodevelopmental diseases and CHD based on

50	findings from DNMs. Currently, there are few methods that can jointly analyze DNM data on
51	multiple traits. Therefore, we develop a framework to identify risk genes for multiple traits
52	simultaneously for DNM data. The new method is applied to CHD and autism as a case study to
53	demonstrate its improved power in identifying risk genes compared with single-trait analysis.
54	Our results lead to new insights on the disease etiology of CHD, and the shared etiological
55	mechanisms between CHD and autism.
56	
57	
58	
59	
60	
0.4	
61	
62	
63	
64	
65	
67	
68	
60	
70	
71	
72	

# 73 Introduction

Congenital heart disease (CHD) is the most common birth defect. It affects 0.8% of live birth
and accounts for one-third of all major congenital abnormalities [1, 2]. CHD is associated with
both genetic and environmental factors [2]. It is genetically heterogenous and the estimated
heritability in a Danish twin study is close to 0.5 [3].

78

79 Studies on *de novo* mutations (DNMs) have been successful in identifying risk genes for early 80 on-set diseases as DNMs with deleterious effects have not been through natural selection. By 81 conducting whole-exome sequencing (WES) studies for parent-offspring trios, there are 82 cumulative findings of potential risk genes for CHD and neurodevelopmental disorders by 83 identifying genes with more DNMs than expected by chance [4-6]. However, the statistical 84 power for identifying risk genes is still hampered by the limited sample size of WES due to its 85 relatively high cost in recruiting and sequencing samples, as well as the low occurrence of 86 DNMs given its rarity.

87

88 Meta-analysis and joint analysis are two major approaches to improve the statistical power by 89 integrating information from different studies. Meta-analysis studies on WES DNMs and 90 Genome-wide Association Studies (GWAS) for multiple traits have been conducted [7, 8]. 91 However, these approaches may overlook the heterogeneity among traits, thus hinder the ability 92 to interpret finding for each single trait. By identifying the intersection of top genes from multiple 93 traits, some recent studies have shown that there are shared risk genes between CHD and 94 autism [9, 10]. Shared disease mechanism for early-onset neurodevelopmental diseases has 95 also been reported [11, 12]. Based on these findings, joint analysis methods have been 96 proposed and gained success in GWAS and expression quantitative trait loci (eQTL) studies. 97 Studies have shown that multi-trait analysis can improve statistical power [13-19] and accuracy

of genetic risk prediction [20-22]. Currently, there lacks joint analysis methods to analyze DNM
data on multiple traits globally, with the exception of mTADA [23].

100

101 In addition to joint analysis, integrating functional annotations has also been shown to improve 102 statistical power in GWAS [15, 24] and facilitate the analysis of sequencing studies [25] [26]. 103 There is a growing number of publicly available tools to annotate mutations in multiple 104 categories, such as the genomic conservation, epigenetic marks, protein functions and human 105 health. With these resources, there is a need to develop a statistical framework for jointly 106 analyzing traits with shared genetic architectures and integrating functional annotations for DNM 107 data. 108 109 In this article, we propose a Multi-trait *De novo* mutation Association Test with Annotations, 110 named M-DATA, to identify risk genes for multiple traits simultaneously based on pleiotropy and 111 functional annotations. We demonstrate the performance of M-DATA through extensive 112 simulation studies and real data examples. Through simulations, we illustrate that M-DATA is 113 able to accurately estimate the proportion of disease-causing genes between two traits under 114 various genetic architectures. M-DATA outperformed single-trait approaches and methods even 115 if annotation information was not used. Annotations can further boost the power of M-DATA. We 116 applied M-TADA to identify risk genes for CHD and autism. There are 23 genes discovered to

117 be significant for CHD, including 12 novel genes, bringing novel insight to the disease etiology

118 of CHD.

119

120

121 122

### 123 Methods

#### 124 Probabilistic model

- 125 First, we consider the simplest case with only one trait, and then we extend our model to
- multiple traits. We denote  $Y_i$  as the DNM count for gene *i* in a case cohort, and assume  $Y_i$  come
- 127 from the mixture of null ( $H_0$ ), and non-null ( $H_1$ ), with proportion  $\pi_0 = 1 \pi$  and  $\pi_1 = \pi$
- 128 respectively. Let  $Z_i$  be the latent binary variable indicating whether this gene is associated with
- the trait of interest, where  $Z_i = 0$  means gene *i* is unassociated ( $H_0$ ), and  $Z_i = 1$  means gene *i*
- 130 is associated  $(H_1)$ . Then, we have the following model:

$$Z_{i} \sim Bernoulli(\pi)$$
$$Y_{i}|Z_{i} = 0 \sim Poisson(2N\mu_{i})$$
$$Y_{i}|Z_{i} = 1 \sim Poisson(2N\mu_{i}\gamma_{i})$$

131 where N is the sample size of the case cohort,  $\mu_i$  is the mutability of gene *i* estimated using the 132 framework in Samocha, Robinson (27), and  $\gamma_i$  is the relative risk of the DNMs in the risk gene 133 and is assumed to be larger than 1. The derivation of the parameter of the Poisson distribution 134 is the same as that in TADA [6, 28]. We define this model as the single-trait model without 135 annotation in our main text.

136

137 To leverage information from functional annotations, we use an exponential link between  $\gamma_i$  and 138  $X_i$ ,

$$\gamma_i = exp(X_i^T\beta),$$

139 where  $X_i^T$  is the transpose of the functional annotation vector of gene *i*, and  $\beta$  is the effect size 140 vector of the functional annotations. Under the assumption that risk genes have higher burden 141 than non-risk genes, we expect the estimated value of  $\gamma_i$  to be larger than 1.

143 Now we extend our model to consider multiple traits simultaneously. To unclutter our notations, we present the model for the two-trait case. Suppose we have gene counts  $Y_{i1}$  and  $Y_{i2}$  for gene 144 145 *i* from two cohorts with different traits. Similarly, we introduce latent variables 146  $Z_i = [Z_{i00}, Z_{i10}, Z_{i01}, Z_{i11}]$  to indicate whether gene *i* is associated with the traits. Specifically,  $Z_{i00} = 1$  means the gene *i* is associated with neither trait,  $Z_{i10} = 1$  means that it is only 147 148 associated with the first trait,  $Z_{i01} = 1$  means that it is only associated with the second trait, and  $Z_{i11} = 1$  means that it is associated with both traits. Then, we have: 149 150  $Z_i \sim Multinomial(1, \pi)$ , with  $\pi = (\pi_{00}, \pi_{10}, \pi_{01}, \pi_{11})$ 151  $\pi_{00} = \Pr(Z_{i00} = 1), Y_{i1} | Z_{i00} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i00} \sim Poisson(2N_2\mu_i)$  $\pi_{10} = \Pr(Z_{i10} = 1), Y_{i1} | Z_{i10} \sim Poisson(2N_1\mu_i\gamma_{i1}), Y_{i2} | Z_{i10} \sim Poisson(2N_2\mu_i)$ 152  $\pi_{01} = \Pr(Z_{i01} = 1), Y_{i1} | Z_{i01} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i01} \sim Poisson(2N_2\mu_i\gamma_{i2})$ 153  $\pi_{11} = \Pr(Z_{i11} = 1), Y_{i1} | Z_{i11} \sim Poisson(2N_1\mu_i\gamma_{i1}), Y_{i2} | Z_{i11} \sim Poisson(2N_2\mu_i\gamma_{i2})$ 154  $\gamma_{i1} = \exp(X_{i1}^T \beta_1), \gamma_{i2} = \exp(X_{i2}^T \beta_2)$ 155 156 where  $\pi$  is the corresponding risk proportion of genes belonging to each class, with 157  $\sum_{l \in \{00,10,01,11\}} \pi_l = 1$ . Then, the risk proportion of the first trait and second trait is  $\pi_{10} + \pi_{11}$  and  $\pi_{01} + \pi_{11}$ , respectively. When there is no pleiotropy of the two traits,  $\pi_{11} = (\pi_{10} + \pi_{11})(\pi_{01} + \pi_{11})$ 158  $\pi_{11}$ ). The difference between  $\pi_{11}$  and  $(\pi_{10} + \pi_{11})(\pi_{01} + \pi_{11})$  reflects the magnitude of global 159 160 pleiotropy between the two traits.  $\mu_i$  is the same as our one-trait model.  $N_1$ ,  $\gamma_{i1}$  and  $X_{i1}$  are the case cohort size, relative risk and annotation vector of gene *i* for the first trait.  $N_2$ ,  $\gamma_{i2}$  and  $X_{i2}$  are 161

162 similarly defined for the second trait.

163

164 Denote  $\theta = (\pi, \beta_1, \beta_2)$  the parameters to be estimated in our model. As we only consider *de* 165 *novo* mutations, they can be treated as independent as they occur with very low frequency. The 166 full likelihood function can be written as

$$L(\Theta) = \prod_{i=1}^{M} \sum_{l \in \{00, 10, 01, 11\}} [\pi_{l} \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \Theta)]^{Z_{il}}$$

167 where M is the number of genes. The log-likelihood funciton is

$$l(\Theta) = \sum_{i=1}^{M} \log \sum_{l \in \{00,10,01,11\}} [\pi_l \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \Theta)]^{Z_{il}}.$$

168

#### 169 Estimation

170 Parameters of our models can be estimated using the Expectation-Maximization (EM) algorithm

171 [32]. It is very computationally efficient for our model without annotation because we have

172 explicit solutions for the estimation of all parameters in the M-step.

173

174 By Jenson's inequality, the lower bound  $Q(\Theta)$  of the log-likelihood function is

$$l(\Theta) \ge Q(\Theta) = \sum_{i=1}^{M} \sum_{l \in \{00,10,01,11\}} \left[ Z_{il} [\log(\pi_l) + \log(\Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \Theta))] \right].$$

175

The algorithm has two steps. In the E-step, we update the estimation of latent variables  $Z_{il}, l \in \{00, 01, 10, 11\}$  by its posterior probability under the current parameter estimates in round s.

178 That is,

$$Z_{il}^{(s)} = \Pr(Z_{il} = 1 | Y_{i1}, Y_{i2}; \Theta^{(s)}) = \frac{\Pr(Z_{il} = 1, Y_{i1}, Y_{i2} | \Theta^{(s)})}{\Pr(Y_i | \Theta^{(s)})}$$
$$= \frac{\Pr(Z_{il} = 1 | \Theta^{(s)}) \Pr(Y_{i1}, Y_{i2} | Z_{il} = 1; \Theta^{(s)})}{\sum_{l^{'} \in \{00, 01, 10, 11\}} \left[\Pr(Z_{il^{'}} = 1 | \Theta^{(s)}) \Pr(Y_{i1}, Y_{i2} | Z_{il^{'}} = 1; \Theta^{(s)})\right]}.$$

179

180 In the M-step, we update the parameters in  $\theta$  based on the estimation of  $Z_{il}$  in the E-step by

181 maximizing  $Q(\Theta)$ . For  $\pi$ , there is an analytical solution, which is

$$\pi_{l}^{(s+1)} = \frac{\sum_{i=1}^{M} Z_{il}^{(s)}}{M}$$

182

183 For the rest of derivation, we take the estimation process for the first trait as an example. Taking

184 the first order derivative of  $Q(\Theta)$  with respect to  $\beta_1$  as 0, we have

185 
$$d_{\beta_1} Q(\Theta)^{(s)} = \sum_{i=1}^M (Z_{i10} + Z_{i11}) (Y_{i1} X_{i1} - 2N_1 \mu_i \exp(X_{i1}^T \beta_1) X_{i1}) = 0.$$

186

187 If we do not add any functional annotations to our model ( $X_{i1}$  degenerates to 1 and  $\beta_1$ 

188 degenerates to a scalar), there exists an analytical solution for  $\beta_1$ .

$$\beta_1^{(s+1)} = \log \frac{\sum_{i=1}^{M} Y_{i1}(Z_{i10} + Z_{i11})}{\sum_{i=1}^{M} 2N_1 \mu_i(Z_{i10} + Z_{i11})}$$

189

However, there is no explicit solution for  $\beta_1$ , so we adopt the Newton-Raphson method for estimation after adding functional annotations into our model. The second-order derivatives for  $Q(\theta)$  is

$$d_{\beta_1}^2 Q(\Theta) = -\sum_{i=1}^M (Z_{i10} + Z_{i11}) (2N_1 \mu_i \exp(X_{i1}^T \beta_1) X_{i1} X_{i1}^T),$$

193 Then, the estimate of  $\beta_1$  can be obtained as

$$\beta_1^{(s+1)} = \beta_1^{(s)} - \left[ d_{\beta_1}^2 Q(\Theta)^{(s)} \right]^{-1} d_{\beta_1} Q(\Theta)^{(s)},$$

194

#### 195 Functional Annotation and Feature Selection

As we have discussed, there are multiple sources of functional annotations for DNMs. For genelevel annotations, we can directly plug into our gene-based model. For variant-level annotations, it is important to collapse the variant-level information into gene-level without diluting useful information. Simply pulling over variant-level annotations of all base pairs within a gene may not be the best approach. To better understand the relationship, we calculate the likelihood ratio of

the DNM counts under  $H_1$  and  $H_0$ . Under  $H_1$ , for all positions t within a gene *i*, the DNM count

202  $Y_{it}$  follows the Poisson distribution with relative risk  $\gamma_{it}$  and mutability  $\mu_{it}$ , then we have

$$\frac{P(Y_i|H_1)}{P(Y_i|H_0)} = \frac{\prod_t P(Y_{it}|H_1)}{\prod_t P(Y_{it}|H_0)} = \frac{\prod_t Poisson(2N\mu_{it}\gamma_{it})}{\prod_t Poisson(2N\mu_{it})},$$

203 where  $\gamma_{it} = \exp(\beta_0 + \beta_1 X_{it})$ . There is likely to be at most one mutation at each position *t* due to

the low frequency of DNM. We can further simplify the above equation to

$$\frac{P(Y_i|H_1)}{P(Y_i|H_0)} = \frac{\prod_t \exp(\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\})\exp(-2N\mu_{it}\exp(\beta_0 + \beta_1 X_{it}))}{\prod_t \exp(-2N\mu_{it})}$$
$$= \exp\left(\sum_t (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\})\exp\left(\sum_t -2N\mu_{it}[\exp(\beta_0 + \beta_1 X_{it}) - 1]\right)\right)$$

205

Assuming the variant-level effect size  $\beta_1$  is small, we can apply Taylor expansion to the second term of the above equation,

$$\frac{P(Y_i|H_1)}{P(Y_i|H_0)} \approx \exp\left(\sum_t (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp\left(\sum_t -2N\mu_{it} [\exp(\beta_0)(1 + \beta_1 X_{it}) - 1]\right)\right)$$

208

209 If we center the collapsed variant-level annotations, we can apply  $\sum_{t} X_{it} = 0$  to the above 210 equation and further simplify it as

$$\frac{P(Y_i|H_1)}{P(Y_i|H_0)} \approx \exp\left(\sum_t (\beta_0 + \beta_1 X_{it} I\{Y_{it} = 1\}) \exp\left(\sum_t -2N\mu_{it} [\exp(\beta_0) - 1]\right)\right)$$
$$= \exp\left(\beta'_0 + \beta'_1 \sum_t (X_{it} I\{Y_{it} = 1\})\right).$$

211

The above approximation motivates us to aggregate variant-level annotations to gene-level annotations by summing up all annotation values of the mutations within a gene after preprocessing each variant-level annotation.

216 We used variant-level annotations from ANNOVAR [29] in our analysis. We define loss-offunction (LoF) as frameshift insertion/deletion, splice site alteration, stopgain and stoploss 217 218 predicated by ANNOVAR, and define deleterious missense variants (Dmis) predicted by 219 MetaSVM [30]. Specifically, we included four categories of features including variant-level 220 deleteriousness (PolyPhen (D), PolyPhen(P) [33], MPC [34], CADD [35], REVEL [36], and LoF), 221 variant-level allele frequencies (gnomAD exome and gnomAD genome [31]), variant-level 222 splicing scores (dbscSNV\_ADA\_score, dbscSNV\_RF\_score [37] and dpsi\_zscore [38]) and 223 dene conservation scores (pLI and mis z) downloaded from gnomAD v2.1.1 [31] in real data 224 analysis. To construct gene-level annotation scores, variant-level annotations were collapsed by 225 summing up values calculated from the mutation information for each gene. All continuous 226 gene-level features were normalized before model fitting.

227

Before performing multi-trait analysis, features were selected separately for each trait by singletrait analysis. For each trait, all gene-level features were evaluated by Pearson's correlation. If the Pearson's correlation between two annotations was larger than 0.7, only one annotation was kept. After model fitting, we kept annotations with the absolute values of effect sizes larger than 0.01 and refit the model with the selected annotations. For multi-trait analyses, we constructed the annotation matrices using the features selected from each trait (see more details in the S1 Text.)

235

#### 236 Hypothesis Testing

Without loss of generality, we take the first trait as an example to illustrate our testing procedure.
After we estimate the parameters, genes can be prioritized based on their joint local false
discovery rate (Jlfdr) [39]. For joint analysis of two traits, the Jlfdr of whether gene *i* is
associated with the first trait is

$$\begin{aligned} \text{JIfdr}_{1}(Y_{i1},Y_{i2}) &= \Pr(Z_{i00} + Z_{i01} = 1 | Y_{i1},Y_{i2}) \\ &= \frac{\pi_{00} \Pr(Y_{i1},Y_{i2} | Z_{i00} = 1; \Theta) + \pi_{01} \Pr(Y_{i1},Y_{i2} | Z_{i01} = 1; \Theta)}{\sum_{l^{'} \in \{00,01,10,11\}} \left[ \pi_{l^{'}} \Pr\left(Y_{i1},Y_{i2} | Z_{il^{'}} = 1; \Theta\right) \right]} \\ &= \frac{\pi_{00} \text{Poisson}(Y_{i1},2N_{1}\mu_{i}) \text{Poisson}(Y_{i2},2N_{2}\mu_{i}) + \pi_{01} \text{Poisson}(Y_{i1},2N_{1}\mu_{i}) \text{Poisson}(Y_{i2},2N_{2}\mu_{i}\gamma_{i2})}{\sum_{l^{'} \in \{00,01,10,11\}} \left[ \pi_{l^{'}} \Pr\left(Y_{i1},Y_{i2} | Z_{il^{'}} = 1; \Theta\right) \right]}, \end{aligned}$$

where  $\gamma_{i1} = \exp(X_{i1}^T \beta_1)$  and  $\gamma_{i2} = \exp(X_{i2}^T \beta_2)$ . When there is no annotation, both  $\beta_1$  and  $\beta_2$ 241 degrade from vectors to single intercept values. Then  $\gamma_{i1}$  and  $\gamma_{i2}$  share the same values  $\exp(\beta_1)$ 242 and  $\exp(\beta_2)$  across all genes. Same formula can be used to compute the Jlfdr of each gene. 243 244 The definition of the Jlfdr is the posterior probability of a null hypothesis being true, given the 245 observed DNM count vector  $(Y_1, Y_2)$ . If we consider the first trait, the corresponding null 246 hypothesis is the gene *i* associates with both traits or only associates with the second trait, i.e.,  $Z_{i00} + Z_{i01} = 1$ . And the corresponding Jlfdr is  $Jlfdr_1(Y_{i1}, Y_{i2}) = Pr(Z_{i00} + Z_{i01} = 1|Y_{i1}, Y_{i2})$ . In 247 248 comparison, the p-value is defined as the probability of observing more extreme results given the null hypothesis being true, i.e., *p*-value= Pr (More extreme than  $(Y_{i1}, Y_{i2})|Z_{i00} + Z_{i01} = 1$ ). To 249 250 compute it, we need to firstly define a partial order for comparing two-dimensional vector  $(Y_1, Y_2)$ , 251 with which the genes associate with the first trait can stand out. One way to define the partial 252 order is to summarize the vector into a one-dimensional test statistic. Since this is not our focus, we will not discuss how to derive a new test statistic in the article. Although the  $Jlfdr_1$  already 253 254 informs the probability of whether the gene is associated with the first trait, we should not 255 directly use it as the p-value to infer the association status due to their different definitions and 256 properties.

257

The following relationship between Jlfdr and false discovery rates (Fdr) was shown in Jiang andYu (39),

260 
$$\operatorname{Fdr}_{1}(\mathcal{R}) = E\left(\operatorname{Jlfdr}_{1}(Y_{1}, Y_{2}) \middle| (Y_{1}, Y_{2}) \in \mathcal{R}\right) \approx \frac{1}{|\{(Y_{i1}, Y_{i2}) \in \mathcal{R}\}|} \sum_{(Y_{i1}, Y_{i2}) \in \mathcal{R}} \operatorname{Jlfdr}_{1}(Y_{i1}, Y_{i2}),$$

261 where the rejection region is the set of two-dimensional vector  $(Y_1, Y_2)$  such that the null 262 hypothesis can be rejected based on a specific rejection criterion. For example, we can specify 263 a rejection criterion to select genes with large values of the weighted average DNM 264 counts:  $0.9Y_1 + 0.1Y_2 \ge 5$ , then the corresponding rejection region is the upper right region above 265 the line of  $0.9Y_1 + 0.1Y_2 = 5$ . Here we omit the gene indicator *i* since the rejection region is 266 defined on DNM count pairs of two traits regardless of the exact gene labels. Jiang and Yu (56) showed that the most powerful rejection region for a given Fdr level q is {Jlfdr,  $(Y_1, Y_2) \le t(q)$ }. 267 268 To determine the threshold t(q), we sort the calculated  $Ilfdr_1$  value of each gene in an 269 ascending order first. Denote the a-th Jlfdr<sub>1</sub> value as Jlfdr<sup>a</sup><sub>1</sub>. We can approximate the Fdr of the region  $\mathcal{R}_a = \{(Y_1, Y_2) | Jlfdr_1(Y_{i1}, Y_{i2}) \leq Jlfdr_1^a\}$  as 270

$$\operatorname{Fdr}\left(\mathcal{R}_{a}\right) = \frac{1}{a} \sum_{b=1}^{a} \operatorname{Jlfdr}_{1}^{b}$$

271 Denote  $c = \max \{a | Fdr(\mathcal{R}_a) \le q\}$ , and then the threshold t(q) for Jlfdr<sub>1</sub> is Jlfdr<sub>1</sub><sup>c</sup>. For testing 272 association with the first trait, we reject all genes with Jlfdr<sub>1</sub>(Y<sub>i1</sub>, Y<sub>i2</sub>)  $\le t(q)$ . For both simulation 273 and real data analyses, the global Fdr is controlled at q = 0.05. The global Fdr is abbreviated as 274 FDR in the following text.

275

#### 276 Implementation of mTADA

We used extTADA [11] to estimate the hyperpriors input for mTADA. For simulation and real data application, we applied 2 MCMC chains and 10,000 iterations as recommended by the authors [23]. We applied PP>0.8 as the threshold for risk gene inference. We benchmarked the computational time of mTADA and M-DATA on Intel Xon Gold 6240 processors (2.6GHZ).-281

#### 282 Misspecified Model

We tested if M-DATA have proper power when functional annotations affect the latent variables  $Z_{il}, l \in \{00,01,10,11\}$  rather than the relative risk parameters  $\gamma_{i1}$  and  $\gamma_{i2}$ . Further, we assumed that the latent variable  $Z_{i10}$  is associated with the functional annotation vector  $X_{i1}$ , which is the functional annotation vector for gene *i* of the first trait,  $Z_{i01}$  is associated with  $X_{i2}$ , which is the functional annotation vector for gene *i* of the second trait, and  $Z_{i11}$  is associated with both  $X_{i1}$ and  $X_{i2}$  through the following forms:

$$P(Z_{i00}) = \frac{1}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}$$

$$P(Z_{i10}) = \frac{\exp(X_{i1}^T \beta_1)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}$$

$$P(Z_{i01}) = \frac{\exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}$$

$$P(Z_{i11}) = \frac{\exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}{1 + \exp(X_{i1}^T \beta_1) + \exp(X_{i2}^T \beta_2) + \exp(X_{i1}^T \beta_1 + X_{i2}^T \beta_2)}$$

289 
$$\pi_{00} = \Pr(Z_{i00} = 1), Y_{i1} | Z_{i00} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i00} \sim Poisson(2N_2\mu_i)$$

290 
$$\pi_{10} = \Pr(Z_{i10} = 1), Y_{i1} | Z_{i10} \sim Poisson(2N_1 \mu_i \gamma_{i1}), Y_{i2} | Z_{i10} \sim Poisson(2N_2 \mu_i)$$

291 
$$\pi_{01} = \Pr(Z_{i01} = 1), Y_{i1} | Z_{i01} \sim Poisson(2N_1\mu_i), Y_{i2} | Z_{i01} \sim Poisson(2N_2\mu_i\gamma_{i2})$$

292 
$$\pi_{11} = \Pr(Z_{i11} = 1), Y_{i1} | Z_{i11} \sim Poisson(2N_1 \mu_i \gamma_{i1}), Y_{i2} | Z_{i11} \sim Poisson(2N_2 \mu_i \gamma_{i2}),$$

293 where  $\pi$  is the corresponding risk proportion of genes belonging to each class, with

294  $\sum_{l \in \{00,10,01,11\}} \pi_l = 1$ . Here,  $\mu_i$  is the mutability of gene *i*.  $N_1$ ,  $\gamma_{i1}$  and  $X_{i1}$  are the case cohort size,

relative risk and annotation vector of gene *i* for the first trait. Similarly,  $N_2$ ,  $\gamma_{i2}$  and  $X_{i2}$  are

296 defined for the second trait.

297

### 298 Verification and Comparison

#### 299 Estimation Evaluation

300 We conducted comprehensive simulation studies to evaluate the estimation and power 301 performance of M-DATA. We set the total number of genes M to 10,000, where genes were 302 randomly selected from gnomAD v2.1 [31]. We set the size of the case cohort at 2000, 5000 303 and 10000, corresponding to a small, medium and large WES study. We assumed the 304 proportion of risk genes to be 0.1 for each trait (i.e.,  $\pi_{10} + \pi_{11} = \pi_{01} + \pi_{11} = 0.1$ ), and varied the 305 shared risk proportion  $\pi_{11}$  at 0.01, 0.03, 0.05, 0.07 and 0.09. When  $\pi_{11} = 0.01$ , it corresponds to 306 the absence of pleiotropy between two traits, and we expect our multi-trait models to perform 307 similarly as our single-trait models. 308

309 We first evaluated the performance of estimation for our models, and then we conducted power 310 analysis for our single-trait models and multi-trait models. To evaluate the estimation 311 performance for multi-trait models, we simulated the true model with two Bernoulli annotations, 312 and set the parameter of the Bernoulli distributions to 0.5 for both traits. We varied the effect 313 sizes of annotations  $(\beta_{i0}, \beta_{i1}, \beta_{i2}), j = 1,2$  from (3,0.1, 0.1) (3,0.1,0) and (3,0,0), which 314 corresponds to the cases when both annotations are effective, only the first annotation is 315 effective and no annotation is effective. We evaluated the estimates of shared proportion of risk genes  $\pi_{11}$  and the risk gene proportion for a single trait. There are in total 27 simulation settings 316 317 for estimation evaluation. To obtain an empirical distribution of our estimated parameters, we 318 replicated the process for 50 times for each setting. We simulated the two traits in a symmetrical 319 way, so we only present the results of the first trait. The performance of estimation under the 320 scenario that both annotations are effective( $(\beta_{i1}, \beta_{i2}) = (0.1, 0.1), j = 1, 2$ ) are shown in Fig 1. 321 The rest of scenarios are shown in Fig A in the S1 Text.

322







330

#### 331 Power Evaluation

332 Given that the effective number of functional annotations for DNM data in real world is unknown, 333 we explored the power performance of single-trait and multi-trait models when annotations are 334 only partially observed. We varied the effect size of annotations from 335 and , which corresponds to the cases when effect of 336 annotations is weak, moderate, and strong. We assumed that only the first two annotations can 337 be observed. We first demonstrated our model can control FDR (Fig B in the S1 Text) under 338 theses settings and then evaluated power (Fig 2), type I error (Fig C in the S1 Text), and AUC (Fig D in the S1 Text) for our single-trait models and multi-trait models. There are in total 45 339

#### 340 simulation settings. Under each setting, the data were simulated based on our multi-trait model



#### 341 with annotations (Methods).



Fig 2. Power performance under different strengths of annotations. The panels from top to bottom show the
power performance under weak, moderate and strong annotations, respectively. For each panel, each plot from left to
right represents study sample size of 2000, 5000, and 10000, respectively. Within each plot, boxes from left to right
represent the proportion of shared risk genes being 0.01, 0.03, 0.05, 0.07 and 0.09, respectively. Each scenario is
replicated for 50 times in our simulations.

349	With the increase of the sample size, the performance of all four models becomes better. Under
350	weak annotations, the power performance of models with annotations and without annotations
351	are comparable. However, when annotations are stronger, the power performance of models
352	with annotations are better than models without annotations (Fig E and Fig F in the S1 Text).
353	With the increase of shared risk proportion, the power performance of multi-trait models become
354	better than single-trait models.
355	
356	Comparison with mTADA
357	Under the same settings in the previous section, we compared the power performance of
358	mTADA and M-DATA. The sample size of the DNM cohort was set as 5000 for both traits. In the
359	simulation, we observed that both methods could control FDR, while mTADA was more
360	conservative than M-DATA for FDR control (Fig G in the S1 Text). M-DATA has higher power
361	than mTADA when the effect size of annotations is larger (Fig 3). The result is consistent with
362	our observation in the real data (Application). In the time comparison, we observed that our
363	method converged faster than the MCMC method adopted by mTADA (Table D in the S1 Text).
364	





Fig 3. Comparisons of M-DATA and mTADA under different strengths of annotations. The panels from top to
bottom show the power performance under weak, moderate and strong annotations, respectively. For each panel,
each plot from left to right represents study sample size of 2000, 5000, and 10000, respectively. Within each plot,
boxes from left to right represent the proportion of shared risk genes being 0.01, 0.03, 0.05, 0.07 and 0.09,

370 respectively. Each scenario is replicated for 50 times in our simulations.

371

#### 372 Robustness to Model Misspecification

373 We also evaluated the power performance of M-DATA under misspecified models (Methods),

- 374 where we simulated two Bernoulli annotations that affect the latent variables
- 375  $Z_{il}, l \in \{00, 10, 01, 11\}$ , and set the parameter of the Bernoulli distributions to 0.5 for both traits.
- We varied the effect sizes of annotations on the latent variables  $(\beta_{i0}, \beta_{i1}, \beta_{i2}), j = 1, 2$  at (-
- 377 3,0.5,0.5), (-3,1,1) and (-3,1.5,1.5), which corresponds to the case when the effect of
- annotations is weak, moderate, and strong, respectively. The relative risk parameters  $\gamma_{i1}$  and
- 379  $\gamma_{i2}$  were set at 25. We simulated DNM counts under this misspecified model and evaluated the
- 380 performance of M-DATA multi-trait models for different sizes of DNM cohort (1000, 2000, and
- 381 4000). We observed that M-DATA can control FDR under all settings and the multi-trait model
- 382 with annotations had better power than the multi-trait model without annotation with the increase
- 383 of the effect size of annotations (Fig 4).









386 power and FDR under weak, moderate and strong annotations on the latent variables

387 respectively. For each panel, each plot from left to right represents study sample size of 1000, 2000, and 4000,

388 respectively. Each scenario is replicated for 50 times in our simulations.

389

# 390 Application

- 391 We applied M-DATA to real DNM data from 2,645 CHD probands reported in Jin et al. [4] and
- 392 5,623 autism probands acquired from denovo-db [40]. We only considered damaging mutations
- 393 (LoF and Dmis) in our analysis as the number of non-deleterious mutations is not expected to
- 394 provide information to differentiate cases from controls biologically [41]. Details of functional

annotation and feature selection are included in Methods and S1 Text. In total, there were
18,856 genes tested by M-DATA.

397

398 We performed single-trait analysis on CHD and autism data separately, followed by joint 399 analysis both CHD and autism data with the multi-trait models. We compared the performance 400 of single-trait models and multi-trait models for CHD under different significance thresholds. 401 With a stringent significance threshold (i.e., FDR < 0.01), single-trait model without annotation 402 identified 8 significant genes, single-trait model with annotation identified 10 significant genes, 403 multi-trait model without annotation identified 11 significant genes, and multi-trait model with 404 annotation identified 14 genes. With FDR < 0.05, single-trait model without annotation identified 405 15 significant genes, single-trait model with annotation identified 19 significant genes, multi-trait 406 model without annotation identified 18 significant genes, and multi-trait model with annotation 407 identified 23 significant genes (Table 1). It demonstrates that M-DATA is able to identify more 408 genes by jointly analyzing multiple traits and incorporating information from functional 409 annotations. We visualized the identified genes with Venn diagrams (Fig 5 and Fig H in Text S1).

	Model	FDR<0.05	FDR<0.01	
	Single no Anno: CHD/Autism	15/28	8/17	
	Single with Anno: CHD/Autism	19/35	10/22	
	Multi no Anno: CHD/Autism	18/28	11/19	
	Multi with Anno: CHD/Autism	23/37	14/23	
410	Table 1. Results for M-DATA Sing	le-Trait and Multi-T	rait Models	
411				
412	We further demonstrate the results by taking CHD as an example. Compared with the single			
413	trait model without annotation, the multi-trait model without annotation identified 3 additional			
414	genes, which are FRYL, NAA15 and PTEN. Compared with the single-trait model with			
415	annotations, the multi-trait model with annotations identified 6 additional genes, including			ding

416 CDK13, FRYL, LZTR1, NAA15, PTEN and RPL5. There are two additional genes identified by

- 417 the single-trait model with annotations, but not the multi-trait models. Both of these two genes
- 418 did not have DNMs in autism and are around the margin of FDR threshold (0.05) for the multi-
- 419 trait model with annotations (AHNAK 0.056, MYH6 0.061).
- 420



Fig 5. Venn diagram of identified genes in different models. Compared to the single-trait model without
annotation, the single-trait model with annotations identified 4 additional genes. Compared to the multi-trait model
without annotation, the multi-trait model with annotations identified 5 additional genes. In total, the multi-trait models
identified 6 different genes compared to the single-trait models, including 4 novel human CHD genes (*CDK13, FRYL*, *LZTR1* and *NAA15*).

427

428 To further illustrate the gain of power from multi-trait analysis, we visualized the posterior

- 429 probability of being shared risk gene for CHD and autism of identified genes in the multi-trait
- 430 model with annotations in Fig 6A (CHD) and Fig I in the S1 Text (autism). In the main text, we
- 431 further illustrate the results with the 23 significant CHD genes. All genes identified by the multi-

<sup>421</sup> 

432 trait models are annotated with gene names, and the 6 additional genes identified by multi-trait 433 analyses are colored red. From this figure, we can see that most genes (5/6) have high 434 posterior probability of being shared. RPL5 is at the margin of FDR threshold in the single-trait 435 models and may be prioritized in the multi-trait models by chance (Fig 6B). In addition, we 436 checked the correlation between the FDR of top genes identified by the multi-trait model with 437 annotations in the single-trait model with annotations (Fig 6B). All 6 genes have low FDR (<0.2) 438 in the single-trait model with annotations, which indicates multi-trait analysis can prioritize 439 marginal signals in single-trait analysis.





441 442 Fig 6. Multi-trait analyses prioritized additional genes with high posterior probability of being shared risk 443 genes for CHD. Gene names of the 23 genes identified by the multi-trait model with annotations are shown on the 444 plot and the additional 6 genes that were identified by the multi-trait models are marked in red. (A) shows that the 6 445 additional genes identified by the multi-trait models had high posterior probability of being shared. The x-axis 446 represents the posterior probability of being shared calculated from the multi-trait model with annotations. The y-axis 447 represents the FDR of genes calculated from the multi-trait model with annotations. (B) shows that the top genes in 448 the multi-trait model with annotations also had low FDR (<0.2) in the single-trait model with annotations. The x-axis 449 represents the FDR of genes calculated from the single-trait model with annotations. The y-axis represents the FDR 450 of genes calculated from the multi-trait model with annotations.

451 We take the 5 CHD genes identified by the multi-trait models, but not the single-trait models as 452 examples to demonstrate the pleiotropic effect. We selected the DNM counts of CHD and 453 autism, FDR of the single-trait model with annotations and FDR of the multi-trait model with 454 annotations model from the results (Table 2). From this table, we can see CDK13, FRYL, 455 LZTR1. NAA15 and PTEN have 2 DNM counts for CHD and at least 1 shared DNM count with 456 autism. For PTEN, it has 4 shared counts with autism, and we can see a substantial increase of 457 significance in terms of FDR. Thus, the insight is that genes with shared counts with autism are 458 more likely to be prioritized for CHD in multi-trait analyses by leveraging the pleiotropic effect.

Gene	CHD Counts	Autism Counts	FDR Single Anno	FDR Multi Anno
CDK13	2	1	0.137	0.0353
FRYL	2	2	0.172	0.0461
LZTR1	2	1	0.0749	0.0257
NAA15	2	3	0.0609	0.00726
PTEN	2	4	0.151	0.00882

459

Table 2. Pleiotropic effect boosts power for M-DATA multi-trait models.

460

461 Among the 23 identified genes from joint model with annotations, 11 were well established

462 known CHD genes based on a previously compiled gene list with 254 known CHD genes [4].

463 They are involved in essential developmental pathways or biological processes, such as Notch

464 signaling (NOTCH1), RAS signaling (PTPN11, RAF1, SOS1), PI3K/AKT signaling (PTEN),

465 chromatin modeling (CHD7, KMT2D, NSD1), transcriptional regulations (GATA6), and cell

466 structural support (ACTB, RPL5) [42, 43].

468	Among the 12 novel genes, RBFOX2, SMAD2, CDK13 are three emerging CHD risk genes that
469	have been recently reported to cause hypoplastic left heart syndrome [9, 44, 45], laterality
470	defect [1, 46], and septal defects and pulmonary valve abnormalities [47], respectively.
471	
472	Additionally, 4 novel genes, POGZ, KDM5B, NAA15, and FRYL, harbored at least two de novo
473	mutations in both CHD and autism cohorts.
474	
475	POGZ, encoding a heterochromatin protein 1 alpha-binding protein, participates in chromatin
476	modeling and gene regulations. It binds to chromatin and facilitates the packaging of DNA onto
477	chromosomes. POGZ damaging de novo mutations were strongly linked with autism spectrum
478	disorders and other neurodevelopmental disorders [48, 49]. Interestingly, one of the reported
479	mutation carriers also presented cardiac defect [50].
480	
481	KDM5B is a lysine-specific histone demethylase. Studies have shown that it regulates H3K4
482	methylation near promoter and enhancer regions in embryonic stem cells and controls the cell
483	pluripotency [51, 52]. The deletion of KDM5B in mice is neonatal lethal with respiratory failure
484	and neurodevelopmental defects [53]. Recessive mutations in the gene were associated with
485	mental retardation (OMIM: 618109) and one reported patient presented atrial septal defect.
486	
487	NAA15 encodes the auxiliary subunit of N-Alpha-Acetyltransferase 15, which catalyzes one of
488	the most common post-translational modification essential for normal cell functions. Protein-
489	truncating mutations in NAA15 were reported in intellectual disability and autism patients, some
490	of whom also presented a variety of cardiac abnormalities including ventricular septal defect,
491	heterotaxy, pulmonary stenosis and tetralogy of Fallot [54].

492

*POGZ, KDM5B*, and *NAA15* are all highly expressed in developmental heart at mice embryonic
day E14.5 [4]. *POGZ* and *NAA15* are intolerant for both LoF and missense mutations, given that
they have a pLI score > 0.9 and a missense z-score > 3. *KDM5B* is intolerant for missense
mutations with a missense z-score of 1.78. Considering their intolerance of protein-altering
variants, the identification of damaging *de novo* mutations in them is highly unlikely. Therefore,
our analyses suggest that *POGZ, KDM5B* and *NAA15* may be considered as new candidate
CHD genes.

500

501 Furthermore, among the 17 genes with at least one *de novo* mutation in CHD and autism

502 cohorts, 5 genes (*KMT2D*, *NSD1*, *POGZ*, *SMAD2*, *KDM5B*) play a role in chromatin modeling.

503 Such high proportion is consistent with previous studies that chromatin modeling-related

transcriptional regulations are essential for both cardiac and neuro-development, and genes

505 with critical regulatory roles in the process may be pleotropic [9].

506

507 Further, we compared the performance of M-DATA with mTADA [23] using the same real data 508 of CHD and autism. We fitted both methods with damaging mutations (LoF and Dmis mutations). 509 mTADA identified all 18 genes identified by our no annotation model, and missed 3 genes 510 (CDK13, SAMD11, and RPL5) identified by our annotation model for CHD (Table 2). We 511 visualized the results with Venn diagrams (Fig 6 and Fig J in the S1 Text). We also compared 512 our results with the results of CHD-ASD pair reported by mTADA using CHD data [55] autism 513 data [11], and mutability data downloaded from the github webpage of mTADA (Table E in the 514 S1 Text).

	M-DATA No	M-DATA Anno	mTADA
CHD	18	23	20
Autism	28	37	28

515

Table 3. Comparison of M-DATA multi-trait models with mTADA





Fig 7. Venn diagram of genes identified by M-DATA and mTADA for CHD. M-DATA multi-trait model with
annotations identified 3 additional genes (*CDK13, SAMD11* and *RPL5*).

519

# 520 Discussion

521 In this paper, we have introduced M-DATA, a method to jointly analyze de novo mutations from 522 multiple traits by integrating shared genetic information across traits. The implemented model is 523 available at https://github.com/JustinaXie/MDATA. This approach can increase the effective 524 sample size for all traits, especially for those with small sample size. M-DATA also provides a 525 flexible framework to incorporate external functional annotations, either variant-level or gene-526 level, which can further improve the statistical power. Through simulation study, we 527 demonstrated that our multi-trait model with annotations could not only gain accurate estimates 528 on the proportion of shared risk genes between two traits and the proportion of risk genes for a 529 single trait under various settings, but also gained statistical power compared to the single-trait 530 models. In addition, M-DATA adopts the Expectation-Maximization (EM) algorithm in estimation,

which does not require prior parameter specification or pre-estimation. In our simulation study,
we found that the algorithm converges faster than methods that use MCMC for estimation
(Table D in the S1 Text).

534

535 Despite the success, there are some limitations in the current M-DATA model. In our real data 536 analysis, we used two different data sources for CHD and autism. Samples with both diseases 537 in our multi-trait analysis may bring bias because of the violation of independence assumption in 538 our multi-trait models. The autism DNM data in our analysis are from different studies, and 539 different filtering criteria across studies may also bring bias and dilute our signals. In addition, 540 we only considered two traits simultaneously. Though it is straightforward to extend our model 541 to more than two traits, the number of groups (i.e., the dimension of latent variables  $Z_i$ ) 542 increases exponentially with the number of traits ( $2^N$  for N traits) [23]. This might bring difficulty 543 in estimation and have more computational cost. Model performance with more than two traits 544 need further exploration. Currently, we did not consider the influence of admixed population in 545 M-DATA. In a recent study, Kessler et al. studied DNM across 1,465 diverse genomes and 546 discovered mutation rates may be affected by the environment more significantly than 547 previously known [56]. Confounding from the environment on mutation rates could be further 548 explored through cross-ancestry rare variant studies.

549

In conclusion, M-DATA is a novel and powerful approach to performing gene-based association analysis for DNMs across multiple traits. Not only does M-DATA have better statistical power than single-trait methods, it also provides reasonable estimation of shared proportion of risk genes between two traits, which gives novel insights in the understanding of disease mechanism. We have successfully applied M-DATA to study CHD, which identified significant 23 genes for our multi-trait model with annotations. Moreover, our method provides a general framework in extending single-trait method to multi-trait method which can also incorporate

- 557 information from functional annotations. Recently, there are several advancements in the
- association analysis for rare variants, such as jointly analyzing DNMs and transmitted variants
- 559 [41], analyzing DNMs from whole-genome sequencing (WGS) data [25], and incorporating
- 560 pathway information [57]. Extension of these methods to multi-trait analysis is a potential future
- 561 direction.
- 562

### 563 Ethics Statement

- 564 This study is approved by Yale Human Research Protection Program Institutional Review
- 565 Boards (IRB protocol ID 2000028735).

566

# 567 Supporting Information

- 568 **S1 Table. Simulation of Estimation and Power Evaulation.**
- 569 **S2 Table. Simulation of Comparison with mTADA.**
- 570 S3 Table. Results of Real Data Application.
- 571 S1 Text. Supplementary Notes on Methods and Results.

572

### 573 Acknowledgements

- 574 Supported in part by NIH grant R03HD100883-01A1. We thank Dr. Sheng Chih (Peter) Jin,
- 575 Geyu Zhou and Hanmin Guo for helpful discussions.

576

# 577 **References**

Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, et al. De novo mutations in
 histone-modifying genes in congenital heart disease. Nature. 2013;498(7453):220-3. Epub
 2013/05/12. doi: 10.1038/nature12141. PubMed PMID: 23665959.

Postma AV, Bezzina CR, Christoffels VM. Genetics of congenital heart disease: the
 contribution of the noncoding regulatory genome. Journal of Human Genetics. 2016;61(1):13-9.
 doi: 10.1038/jhg.2015.98.

5843.Wienke A, Herskind AM, Christensen K, Skytthe A, Yashin AI. The heritability of CHD585mortality in danish twins after controlling for smoking and BMI. Twin Res Hum Genet.

2005;8(1):53-9. Epub 2005/04/20. doi: 10.1375/1832427053435328. PubMed PMID: 15836811.
Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49(11):1593-601. Epub 2017/10/11. doi: 10.1038/ng.3970. PubMed PMID: 28991257; PubMed Central PMCID: PMCPMC5675000.

5. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo
mutations revealed by whole-exome sequencing are strongly associated with autism. Nature.
2012;485(7397):237-41. Epub 2012/04/13. doi: 10.1038/nature10945. PubMed PMID:
22495306; PubMed Central PMCID: PMCPMC3667984.

595 6. He X, Sanders SJ, Liu L, De Rubeis S, Lim ET, Sutcliffe JS, et al. Integrated model of de
596 novo and inherited genetic variants yields greater power to identify risk genes. PLoS Genet.
597 2013;9(8):e1003671. Epub 2013/08/24. doi: 10.1371/journal.pgen.1003671. PubMed PMID:
598 23966865; PubMed Central PMCID: PMCPMC3744441.

599 7. Coe BP, Stessman HAF, Sulovari A, Geisheker MR, Bakken TE, Lake AM, et al.

Neurodevelopmental disease genes implicated by de novo mutation and copy number variation
morbidity. Nature Genetics. 2019;51(1):106-16. doi: 10.1038/s41588-018-0288-4.

8. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, et al. Metaanalysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies
fourteen non-HLA shared loci. PLoS Genet. 2011;7(2):e1002004. Epub 2011/03/09. doi:
10.1371/journal.pgen.1002004. PubMed PMID: 21383967; PubMed Central PMCID:
PMCPMC3044685.

Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo mutations
in congenital heart disease with neurodevelopmental and other congenital anomalies. Science.
2015;350(6265):1262-6. Epub 2016/01/20. doi: 10.1126/science.aac9396. PubMed PMID:

610 26785492; PubMed Central PMCID: PMCPMC4890146.

611 10. Willsey AJ, Morris MT, Wang S, Willsey HR, Sun N, Teerikorpi N, et al. The Psychiatric Cell 612 Map Initiative: A Convergent Systems Biological Approach to Illuminating Key Molecular

613 Pathways in Neuropsychiatric Disorders. Cell. 2018;174(3):505-20. Epub 2018/07/28. doi:

614 10.1016/j.cell.2018.06.016. PubMed PMID: 30053424; PubMed Central PMCID:

615 PMCPMC6247911.

616 11. Nguyen HT, Bryois J, Kim A, Dobbyn A, Huckins LM, Munoz-Manchado AB, et al.

617 Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and

618 neurodevelopmental disorders. Genome Med. 2017;9(1):114. Epub 2017/12/22. doi:

619 10.1186/s13073-017-0497-y. PubMed PMID: 29262854; PubMed Central PMCID:

620 PMCPMC5738153.

621 Li J, Cai T, Jiang Y, Chen H, He X, Chen C, et al. Genes with de novo mutations are shared 12. 622 by four neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry. 623 2016;21(2):290-7. Epub 2015/04/08. doi: 10.1038/mp.2015.40. PubMed PMID: 25849321; 624 PubMed Central PMCID: PMCPMC4837654. 625 Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. 13. 626 Bayesian test for colocalisation between pairs of genetic association studies using summary 627 statistics. PLoS Genet. 2014;10(5):e1004383. Epub 2014/05/17. doi: 628 10.1371/journal.pgen.1004383. PubMed PMID: 24830394; PubMed Central PMCID: 629 PMCPMC4022491. 630 Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: 14. 631 challenges and strategies. Nat Rev Genet. 2013;14(7):483-95. Epub 2013/06/12. doi: 632 10.1038/nrg3461. PubMed PMID: 23752797; PubMed Central PMCID: PMCPMC4104202. 633 15. Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to prioritizing 634 GWAS results by integrating pleiotropy and annotation. PLoS Genet. 2014;10(11):e1004787. 635 Epub 2014/11/14. doi: 10.1371/journal.pgen.1004787. PubMed PMID: 25393678; PubMed 636 Central PMCID: PMCPMC4230845. 637 Flutre T, Wen X, Pritchard J, Stephens M. A statistical framework for joint eQTL analysis 16. 638 in multiple tissues. PLoS Genet. 2013;9(5):e1003486. Epub 2013/05/15. doi: 639 10.1371/journal.pgen.1003486. PubMed PMID: 23671422; PubMed Central PMCID: 640 PMCPMC3649995. 641 17. Sul JH, Han B, Ye C, Choi T, Eskin E. Effectively identifying eQTLs from multiple tissues by 642 combining mixed model and meta-analytic approaches. PLoS Genet. 2013;9(6):e1003491. Epub 643 2013/06/21. doi: 10.1371/journal.pgen.1003491. PubMed PMID: 23785294; PubMed Central 644 PMCID: PMCPMC3681686. 645 18. Duong D, Gai L, Snir S, Kang EY, Han B, Sul JH, et al. Applying meta-analysis to genotype-646 tissue expression data from multiple tissues to identify eQTLs and increase the number of 647 eGenes. Bioinformatics. 2017;33(14):i67-i74. Epub 2017/09/09. doi: 648 10.1093/bioinformatics/btx227. PubMed PMID: 28881962; PubMed Central PMCID: 649 PMCPMC5870567. 650 Li G, Jima D, Wright FA, Nobel AB. HT-eQTL: integrative expression quantitative trait loci 19. 651 analysis in a large number of human tissues. BMC Bioinformatics. 2018;19(1):95. Epub 652 2018/03/11. doi: 10.1186/s12859-018-2088-3. PubMed PMID: 29523079; PubMed Central 653 PMCID: PMCPMC5845327. 654 Li C, Yang C, Gelernter J, Zhao H. Improving genetic risk prediction by leveraging 20. 655 pleiotropy. Hum Genet. 2014;133(5):639-50. Epub 2013/12/18. doi: 10.1007/s00439-013-1401-656 5. PubMed PMID: 24337655; PubMed Central PMCID: PMCPMC3988249. 657 21. Maier R, Moser G, Chen GB, Ripke S, Coryell W, Potash JB, et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, 658 659 and major depressive disorder. Am J Hum Genet. 2015;96(2):283-94. Epub 2015/02/03. doi: 660 10.1016/j.ajhg.2014.12.006. PubMed PMID: 25640677; PubMed Central PMCID: 661 PMCPMC4320268. 662 Hu Y, Lu Q, Liu W, Zhang Y, Li M, Zhao H. Joint modeling of genetically correlated 22. 663 diseases and functional annotations increases accuracy of polygenic risk prediction. PLoS Genet.

664 2017;13(6):e1006836. Epub 2017/06/10. doi: 10.1371/journal.pgen.1006836. PubMed PMID:
665 28598966; PubMed Central PMCID: PMCPMC5482506.

866 23. Nguyen T-H, Dobbyn A, Brown RC, Riley BP, Buxbaum JD, Pinto D, et al. mTADA is a
867 framework for identifying risk genes from de novo mutations in multiple traits. Nature
868 Communications. 2020;11(1):2929. doi: 10.1038/s41467-020-16487-z.

Lu Q, Yao X, Hu Y, Zhao H. GenoWAP: GWAS signal prioritization through integrated
analysis of genomic functional annotation. Bioinformatics. 2016;32(4):542-8. Epub 2015/10/28.
doi: 10.1093/bioinformatics/btv610. PubMed PMID: 26504140; PubMed Central PMCID:
PMCPMC5963360.

Liu Y, Liang Y, Cicek AE, Li Z, Li J, Muhle RA, et al. A Statistical Framework for Mapping
Risk Genes from De Novo Mutations in Whole-Genome-Sequencing Studies. Am J Hum Genet.
2018;102(6):1031-47. Epub 2018/05/15. doi: 10.1016/j.ajhg.2018.03.023. PubMed PMID:

676 29754769; PubMed Central PMCID: PMCPMC5992125.

Butkiewicz M, Blue EE, Leung YY, Jian X, Marcora E, Renton AE, et al. Functional
annotation of genomic variants in studies of late-onset Alzheimer's disease. Bioinformatics.
2018;34(16):2724-31. doi: 10.1093/bioinformatics/bty177.

680 27. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al. A

681 framework for the interpretation of de novo mutation in human disease. Nat Genet.

682 2014;46(9):944-50. Epub 2014/08/05. doi: 10.1038/ng.3050. PubMed PMID: 25086666;
683 PubMed Central PMCID: PMCPMC4222185.

Mo Li XZ, Chentian Jin, Sheng Chih Jin, Weilai Dong, Martina Brueckner, Richard Lifton,
Qiongshi Lu, Hongyu Zhao. Integrative modeling of transmitted and *de novo* variants identifies
novel risk genes for congenital heart disease. Quant Biol.0-\${article.jieShuYe}. doi: 10.15302/jqb-021-0248.

Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and
wANNOVAR. Nat Protoc. 2015;10(10):1556-66. Epub 2015/09/18. doi: 10.1038/nprot.2015.105.
PubMed PMID: 26379229; PubMed Central PMCID: PMCPMC4718734.

69130.Kim S, Jhong J-H, Lee J, Koo J-Y. Meta-analytic support vector machine for integrating692multiple omics data. BioData Mining. 2017;10(1):2. doi: 10.1186/s13040-017-0126-8.

693 31. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
694 mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
695 2020;581(7809):434-43. doi: 10.1038/s41586-020-2308-7.

696 32. Moon TK. The expectation-maximization algorithm. IEEE Signal Processing Magazine. 697 1996; 13(6):47-60. doi: 10.1109/79.543975.

698 33. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense

699 mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7.20. Epub

2013/01/15. doi: 10.1002/0471142905.hg0720s76. PubMed PMID: 23315928; PubMed Central
 PMCID: PMCPMC4480630.

702 34. Samocha KE, Kosmicki JA, Karczewski KJ, O'Donnell-Luria AH, Pierce-Hoffman E,

MacArthur DG, et al. Regional missense constraint improves variant deleteriousness prediction.
BioRxiv. 2017:148353.

70535.Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework706for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310-

5. Epub 2014/02/04. doi: 10.1038/ng.2892. PubMed PMID: 24487276; PubMed Central PMCID:
PMCPMC3992975.

709 36. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL:

710 An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum

711 Genet. 2016;99(4):877-85. Epub 2016/09/27. doi: 10.1016/j.ajhg.2016.08.016. PubMed PMID:

712 27666373; PubMed Central PMCID: PMCPMC5065685.

Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants
in the human genome. Nucleic Acids Research. 2014;42(22):13534-44. doi:

715 10.1093/nar/gku1206.

716 38. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RKC, et al. The human 717 splicing code reveals new insights into the genetic determinants of disease. Science.

718 2015;347(6218):1254806. doi: 10.1126/science.1254806.

719 39. Jiang W, Yu W. Controlling the joint local false discovery rate is more powerful than

720 meta-analysis methods in joint analysis of summary statistics from multiple genome-wide

721 association studies. Bioinformatics. 2016;33(4):500-7. doi: 10.1093/bioinformatics/btw690.

72240.Turner TN, Yi Q, Krumm N, Huddleston J, Hoekzema K, HA FS, et al. denovo-db: a723compendium of human de novo variants. Nucleic Acids Res. 2017;45(D1):D804-d11. Epub

- 2016/12/03. doi: 10.1093/nar/gkw865. PubMed PMID: 27907889; PubMed Central PMCID:
  PMCPMC5210614.
- 41. Li M. Gene-based Association Analysis for Genome-wide Association and Whole-exome
  Sequencing Studies: Yale University; 2020.
- 728 42. Zaidi S, Brueckner M. Genetics and Genomics of Congenital Heart Disease. Circ Res.
- 2017;120(6):923-40. Epub 2017/03/18. doi: 10.1161/circresaha.116.309140. PubMed PMID:
  28302740; PubMed Central PMCID: PMCPMC5557504.
- 43. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, et al. Genetic
  Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart
  Association. Circulation. 2018;138(21):e653-e711. Epub 2018/12/21. doi:
- 734 10.1161/cir.00000000000606. PubMed PMID: 30571578; PubMed Central PMCID:
  735 PMCPMC6555769.
- 736 44. McKean DM, Homsy J, Wakimoto H, Patel N, Gorham J, DePalma SR, et al. Loss of RNA
- expression and allele-specific expression associated with congenital heart disease. Nat Commun.
- 738 2016;7:12824. Epub 2016/09/28. doi: 10.1038/ncomms12824. PubMed PMID: 27670201;
  739 PubMed Control PMCD: PMCPMC5052634

739 PubMed Central PMCID: PMCPMC5052634.

74045.Verma SK, Deshmukh V, Nutter CA, Jaworski E, Jin W, Wadhwa L, et al. Rbfox2 function741in RNA metabolism is impaired in hypoplastic left heart syndrome patient hearts. Sci Rep.

742 2016;6:30896. Epub 2016/08/04. doi: 10.1038/srep30896. PubMed PMID: 27485310; PubMed
743 Central PMCID: PMCPMC4971515.

744 46. Granadillo JL, Chung WK, Hecht L, Corsten-Janssen N, Wegner D, Nij Bijvank SWA, et al.
745 Variable cardiovascular phenotypes associated with SMAD2 pathogenic variants. Hum Mutat.

746 2018;39(12):1875-84. Epub 2018/08/30. doi: 10.1002/humu.23627. PubMed PMID: 30157302.

747 47. Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B, et al. Distinct genetic

748 architectures for syndromic and nonsyndromic congenital heart defects identified by exome

- 749 sequencing. Nat Genet. 2016;48(9):1060-5. Epub 2016/08/02. doi: 10.1038/ng.3627. PubMed
- 750 PMID: 27479907; PubMed Central PMCID: PMCPMC5988037.

751 Stessman HAF, Willemsen MH, Fenckova M, Penn O, Hoischen A, Xiong B, et al. 48. 752 Disruption of POGZ Is Associated with Intellectual Disability and Autism Spectrum Disorders. Am 753 J Hum Genet. 2016;98(3):541-52. Epub 2016/03/05. doi: 10.1016/j.ajhg.2016.02.004. PubMed 754 PMID: 26942287; PubMed Central PMCID: PMCPMC4890241. 755 Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, et al. Pathogenic POGZ 49. 756 mutation causes impaired cortical development and reversible autism-like phenotypes. Nat 757 Commun. 2020;11(1):859. Epub 2020/02/28. doi: 10.1038/s41467-020-14697-z. PubMed PMID: 758 32103003; PubMed Central PMCID: PMCPMC7044294 declare no competing interests. 759 50. White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating alleles 760 cause syndromic intellectual disability. Genome Med. 2016;8(1):3. Epub 2016/01/08. doi: 761 10.1186/s13073-015-0253-0. PubMed PMID: 26739615; PubMed Central PMCID: 762 PMCPMC4702300. 763 Kidder BL, Hu G, Zhao K. KDM5B focuses H3K4 methylation near promoters and 51. 764 enhancers during embryonic stem cell self-renewal and differentiation. Genome Biol. 2014;15(2):R32. Epub 2014/02/06. doi: 10.1186/gb-2014-15-2-r32. PubMed PMID: 24495580; 765 766 PubMed Central PMCID: PMCPMC4053761. 767 Kurup JT, Campeanu IJ, Kidder BL. Contribution of H3K4 demethylase KDM5B to 52. 768 nucleosome organization in embryonic stem cells revealed by micrococcal nuclease sequencing. 769 Epigenetics Chromatin. 2019;12(1):20. Epub 2019/04/04. doi: 10.1186/s13072-019-0266-9. PubMed PMID: 30940185; PubMed Central PMCID: PMCPMC6444878. 770 Albert M, Schmitz SU, Kooistra SM, Malatesta M, Morales Torres C, Rekling JC, et al. The 771 53. 772 histone demethylase Jarid1b ensures faithful mouse development by protecting developmental 773 genes from aberrant H3K4me3. PLoS Genet. 2013;9(4):e1003461. Epub 2013/05/03. doi: 774 10.1371/journal.pgen.1003461. PubMed PMID: 23637629; PubMed Central PMCID: 775 PMCPMC3630093 other authors have declared that no competing financial interests exist. 776 Cheng H, Dharmadhikari AV, Varland S, Ma N, Domingo D, Kleyner R, et al. Truncating 54. 777 Variants in NAA15 Are Associated with Variable Levels of Intellectual Disability, Autism 778 Spectrum Disorder, and Congenital Anomalies. Am J Hum Genet. 2018;102(5):985-94. Epub 779 2018/04/17. doi: 10.1016/j.ajhg.2018.03.004. PubMed PMID: 29656860; PubMed Central 780 PMCID: PMCPMC5986698. 781 Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, et al. De novo mutations 55. 782 in congenital heart disease with neurodevelopmental and other congenital anomalies. Science 783 (New York, NY). 2015;350(6265):1262-6. doi: 10.1126/science.aac9396. PubMed PMID: 784 26785492. Kessler MD, Loesch DP, Perry JA, Heard-Costa NL, Taliun D, Cade BE, et al. De novo 785 56. 786 mutations across 1,465 diverse genomes reveal mutational insights and reductions in the Amish 787 founder population. Proceedings of the National Academy of Sciences. 2020;117(5):2560-9. doi: 10.1073/pnas.1902766117. 788 Nguyen TH, He X, Brown RC, Webb BT, Kendler KS, Vladimirov VI, et al. DECO: a 789 57. 790 framework for jointly analyzing de novo and rare case/control variants, and biological pathways. 791 Brief Bioinform. 2021. Epub 2021/04/02. doi: 10.1093/bib/bbab067. PubMed PMID: 33791774. 792